Latest Clinical Research News

Biome Australia Limited has announced encouraging results from functional studies on its probiotic strain BMB18, highlighting its potential to modulate immune responses, reduce inflammation, and support intestinal health. These findings pave the way for targeted clinical research and product innovation.

Aroa Biosurgery has reported its first quarter of positive operating cash flow since listing on the ASX in 2020, alongside robust revenue growth projections and new regulatory approvals across key international markets.

BOD Science has executed an asset sale deed transferring critical intellectual property rights to Optimus Salvus, marking a pivotal step in its Deed of Company Arrangement process.

Biome Australia Limited has expanded its distribution footprint to over 6,000 health retail and practitioner locations, marking a 20% increase in six months and advancing toward its Vision 27 target of 8,000 sites by FY27.

Nyrada Inc. reports promising preclinical results for its lead drug NYR-BI03, showing an 86% cardioprotective effect, alongside a strong financial position bolstered by a AU$3.29 million capital raise. The company has submitted its Phase Ia clinical trial package, setting the stage for human testing.